Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a.

Journal of viral hepatitis - 1 Aug 2011

Zhou Y Q, Wang X H, Hong G H, Zhu Y, Zhang X Q, Hu Y J, Mao Q

Abstract excerpt

The optimal duration of treatment and expected response rate for hepatitis C virus genotype (HCV-6)-infected patients have not been determined. Our aims were to determine the treatment outcome with pegylated interferon (PEG-IFN) plus ribavirin for HCV-6a-infected patients at Southwest Hospital and assess the association of the on-treatment virological response with the sustained virological response (SVR)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Recurrence

Share to Ribavirin

Source

Identifiers

PMID: 21105968
DOI: 10.1111/j.1365-2893.2010.01373.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a.PMID 21105968Read ↗

Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin.Semantic proximity Read ↗

24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial.Semantic proximity Read ↗

A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C.Semantic proximity Read ↗

Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6.Semantic proximity Read ↗

Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis.Semantic proximity Read ↗

Response-guided therapy for patients with hepatitis C virus genotype 6 infection: a pilot study.Semantic proximity Read ↗

Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin.Semantic proximity Read ↗

Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study.Semantic proximity Read ↗

What is the safe duration of therapy for patients infected with HCV genotype 6?Semantic proximity Read ↗

Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1.Semantic proximity Read ↗

Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.